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The prevalence of autism spectrum disorders (ASDs)
is rapidly growing, yet its molecular basis is poorly
understood. Here, we sought to gain a systems-level
understanding of ASD candidate genes by mapping
them onto ubiquitous human protein complexes
and characterizing the resulting complexes. These
studies revealed the role of histone deacetylases
(HDAC1/2) in regulating the expression of ASD ortho-
logs in the embryonic mouse brain. Next, proteome-
wide screens for subunits co-complexed with
HDAC1 and six other key ASD proteins in human
neuronal cells revealed a protein interaction network
that displayed preferential expression in fetal brain
development, exhibited increased deleterious muta-
tions in ASD cases, and encompassed genes
strongly regulated by FMRP and MECP2, mutations
that are causal for fragile X and Rett syndromes,
respectively. Overall, our study reveals molecular
components in ASD, suggests a shared mechanism
between the syndromic and idiopathic forms of
ASDs, and provides a groundwork for analyzing
complex human diseases.
INTRODUCTION
Autism spectrum disorders (ASDs) have a strong genetic
component; however, identifying the associated genetic ele-
ments has been challenging because of extreme locus hetero-
geneity: combining all of the information obtained thus far
reveals a genetic cause for only at most 25% of ASD cases
(Huguet et al., 2013). To date, most ASD-associated genes
have been identified from mutation analyses. However, since
heritable mutations in the extant human populations have
been shaped by mutational stochasticity and natural selection,Celgiven the substantially reduced fertility for males with ASD (Po-
wer et al., 2013), the heritable mutations associated with ASD
might not be able to reach high frequencies and thus might
not be readily captured by typical mutational screens, espe-
cially those targeting common variants (such as genome-wide
association studies). More importantly, since many fundamen-
tally important bioprocesses are implicated in ASD and ASD-
associated genes tend to be essential (Georgi et al., 2013),
deleterious mutations in these genes might not be captured
by any mutational screen unless the mutations are hypomor-
phic. Therefore, many molecular components in ASD have re-
mained unidentified, necessitating the development of new
research strategies.
Integrative analyses have been recently performed to uncover
the hidden genetic architecture in ASD. These include con-
struction of gene co-expression (or functional co-association)
network to identify gene groups relevant to ASD (Gilman et al.,
2011; Parikshak et al., 2013; Willsey et al., 2013) and topological
deconstruction of the global human protein interactome to
reveal molecular pathways in ASD (Hormozdiari et al., 2014; Li
et al., 2014). However, these computational approaches were
at a high-level description rather than grounded on the detailed
mechanisms of action in a specific cellular context. Addi-
tional experimental strategies, such as yeast two-hybrid (Y2H)
screens, have mapped the binary physical interactions for a
selected set of ASD candidates (Corominas et al., 2014; Sakai
et al., 2011). Since Y2H assesses the intrinsic binding capacity
between interacting proteins in a non-native state, it remains
unclear whether the in vitro protein-protein interactions (PPIs)
identified from Y2H will also be observed in a cellular context.
Here, we addressed this by devising a systems framework to
identify human cellular protein complexes associated with ASD.
Unlike previous approaches in which disease-related pathways
are inferred from a collection of individually identified susceptible
loci, our strategy directly investigates protein complexes and is
able to reveal the sets of naturally interacting proteins and path-
ways in ASD.
In fact, by analyzing the ubiquitously expressed protein
complexes and complexes isolated from the neuronal cells,l Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Inc. 361
Figure 1. An Overview of This Study
Major procedures, observations, and conclusions are summarized in each box from step 1 to step 4. We first examined a comprehensive set of ubiquitously
expressed human protein complexes and identified the protein subunits co-complexed with ASD candidate proteins (Step 1). These co-complexed subunits
were functionally characterized and assessed for their phenotypes in mouse mutants (Step 2a). As a case study, HDAC1/2 in the NuRD chromatin remodeling
complex were surveyed for their roles in regulating ASD candidate genes in mouse embryonic brain (Step 2b). Immunoprecipitation combined with mass
spectrometry (IP-MS) analysis was performed in neuron-like cells to derive the co-complexed subunits with seven key ASD-associated proteins (step 3). This
neuronal network was further functionally characterized for their temporal expression dynamics during neocortical development. The network identified novel
components with increased rate of deleterious mutations in ASD cases, as well as those regulated by the ASD-associated syndromic factors, FMRPI304N and
MECP2, which are causal for FXS (Fragile X) and Rett syndromes, respectively (Step 4).we identified several key components in ASD that have not yet
been reported previously (Figure 1). Our analysis also revealed
the convergent regulation of two key syndromic regulators,
FMRP (mediating translational inhibition, causal for Fragile X
syndrome [FXS]) and MECP2 (a DNA methylation binding pro-
tein, causal for Rett syndrome), which each operate on the
protein complex targets identified in this study. Most notably,
our results not only unravel the genetic architecture of ASD by
complementing the mutation screens in standard sequencing,362 Cell Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Incbut also extend this analytical approach towards identifying
disease-relevant pathways in other complex human diseases.
RESULTS
Identification of Ubiquitous Human Protein Complexes
in ASD
Several fundamental bioprocesses have been implicated in
ASD, such as translation (Santini et al., 2013) and chromatin.
Figure 2. Human Protein Complexes in ASD
(A) An overview of the ASD-associated proteins in the 622 stable protein complexes from the co-fractionation study (Havugimana et al., 2012), where the Mi-2/
NuRD and the SWI/SNF complexes are shown as examples. Nodes represent the ASD-associated proteins (red) and their co-complexed subunits (purple).
Proteins with inconsistent gene name mapping were not colored.
(B) Differential GO term enrichment (analyzed by ClueGO) between the genes co-complexed with ASD and those with non-ASD genes. Each node is represented
with one GO term, and the edges represent term-term similarity. The color gradient indicates the gene percentage difference of each term between the two
complex groups. The node size indicates the statistical enrichment of a given node.
(C) Enriched mammalian phenotypes for the subunits co-complexed with ASD candidate or control proteins.remodeling, suggesting that many ASD candidate genes are
likely ubiquitously expressed. We thus explored the ubiqui-
tously expressed human protein complexes to identify the
subunits co-complexed with known ASD candidate proteins.
We examined a comprehensive list of 622 soluble stable pro-
tein complexes derived from a recent study based on high-
throughput complex fractionation followed by mass spectrom-
etry (MS) (Havugimana et al., 2012). This dataset represents an
extensive systematic search for human protein complexes.
Compared with individually curated protein complexes from
the literature, this set of 622 complexes is expected to have
significantly less ascertainment bias. The original study showed
that these complexes have high abundance across diverse
human tissues, including the human brain (Havugimana et al.,
2012), which were subsequently validated by our own RNA-
Seq data from tissues collected from the postmortem dorsolat-
eral prefrontal cortex (Supplemental Experimental Procedures;
Figure S1).
We analyzed 378 ASD-associated genes affected by different
types of ASD-associated mutations, including high-confidence
ASD-associated de novo CNVs (copy number variants) (NohCelet al., 2013), syndromic mutations (from Simons Foundation for
Autism Research Initiative [SFARI] annotations, Category S),
and de novo loss-of-function mutations from recent exome-
sequencing studies (Iossifov et al., 2012; Neale et al., 2012;
O’Roak et al., 2012; Sanders et al., 2012; Willsey et al., 2013)
(Supplemental Experimental Procedures; Table S1). These 378
genes mapped to 98 distinct protein complexes (Figure 2A; Ta-
ble S2), which implicated several complexes to ASD, including
the chromatin remodeling SWI/SNF complex involving the well-
known BAF subunits in many neuropsychiatric diseases (Ronan
et al., 2013) (Figure 2A). It is known that ASD candidates are en-
riched for synaptic and chromatin-remodeling proteins (De Ru-
beis et al., 2014), many of which form protein complexes to
achieve their functions; therefore, it is less interesting to simply
test whether ASD proteins are preferentially involved in protein
complexes. Meanwhile, we cannot test whether a given complex
is enriched for subunits encoding ASD genes since a single
subunit could associate the entire protein complex with ASD,
such as the autism susceptibility candidate 2 (AUTS2) in the Pol-
ycomb repressive complex 1 (Gao et al., 2014). We postulated
that if protein complexes represent functional units on whichl Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Inc. 363
disease-associated mutations converge, we expect to see that
subunits co-complexed with known ASD candidates are also
likely involved in this disease. We thus directly tested this
hypothesis.
Since the vast majority of the ASD candidates (>86%) in this
study were from previous screens for de novo mutations (with
many spontaneous syndromic mutations), as a matched con-
trol set, we considered 592 genes affected by de novo loss-
of-function mutations or exon-affecting CNVs from unaffected
siblings or healthy control subjects in previous studies (Supple-
mental Experimental Procedures); these mapped to 87 protein
complexes. We found that that the sizes of the complexes
harboring ASD candidates did not significantly differ from those
encompassing the control proteins (p = 0.31, Wilcoxon rank-
sum test).
Excluding the ASD candidates and the control proteins, we
compared the functional differences between the two sets of
protein complex subunits based on ClueGo (Bindea et al.,
2009). Notably, the enriched Gene Ontology (GO) terms for the
subunits co-complexed with the ASD candidates were highly
divergent from those of the subunits co-complexed with the
control proteins. Specifically, two major functional components
(Figure 2B), intracellular transport (adjusted p = 3.8e-15, hyper-
geometric test corrected by Bonferroni stepdown) and ATP-
dependent chromatin remodeling (adjusted p = 3.8e-6) exhibited
significant functional specificities for the subunits co-complexed
with ASD candidates, encompassing the individually enriched
terms such as mRNA export (adjusted p = 7.8e-4), protein trans-
membrane transport (adjusted p = 3.21e-5), and the NuRD
(Nucleosome Remodeling Deacetylase) complex (adjusted p =
8.3e-5). Several individual terms outside of the two main func-
tional components also showed enrichment, such as membrane
docking (adjusted p = 0.03) and exocyst (adjusted p = 4e-3). In
contrast, the functional specificities (Figure 2B) of the control
subunits largely reflect a background enrichment of the entire
set of ubiquitous complexes.
We next performed the same analysis on the morphological
traits of the orthologous mouse mutants and observed that the
subunits co-complexedwith ASD candidates showed significant
enrichment for abnormal brain and neuron morphology, as well
as for abnormal nervous system and neurodegeneration (Fig-
ure 2C, adjusted p% 0.05; Table S2). These terms were insignif-
icant for the subunits co-complexed with the control proteins
(adjusted pR 0.12). Taken together, these comparisons suggest
ASD association of the subunits co-complexed with known ASD
candidates and a role for intracellular transport and chromatin
remodeling underpinning this disease.
HDAC1/2 Regulates ASD-Associated Genes in the
Embryonic Mouse Brain
To investigate how the ubiquitous protein complexes could
achieve brain-specific functions, we specifically chose the NuRD
complex as it is ubiquitous in different cell types and has been
recently shown to regulate synaptic connectivity in the rodent
cerebellar cortex (Yamada et al., 2014). NuRD contains two sub-
units affected by ASD-associated CNVs (Figure 2A); one of these
isHdac1 inmouse that targets theNuRD to specific chromosomal
locations and is involved in the differentiation of presynaptic sites
(Yamada et al., 2014). In humans, 11HDACs have been identified,364 Cell Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Incbut onlyHDAC1/2 are subunits of theNuRDcomplex, highlighting
their functional divergence from other HDACs. Although HDACs
have been associated with fear, memory, stress, depression,
schizophrenia (SZ), and Alzheimer’s disease (ALZ) (Volmar and
Wahlestedt, 2015), their direct role in ASD has not been estab-
lished. Pharmacological studies have shown that the administra-
tion of HDAC inhibitors (pan specific or those only specific for
HDAC1-3) could ameliorate deficits in cognition and social inter-
action in a rodent model of ASD (Foley et al., 2012). Given the
recent availability of Hdac1/2 knockout data in the embryonic
mouse brain (Hagelkruys et al., 2014), it has become possible
now to studyHdac1/2 for their potential involvement inASD-asso-
ciated pathways.
Hdac1andHdac2havepartially redundant functions in the em-
bryonic mouse brain (Hagelkruys et al., 2014), and we therefore
examined the transcriptome response in the embryonic mouse
brain when both genes were deleted (Hdac1D/DnHdac2D/Dn) at
embryonic day 14.5 (E14.5), the time point in which severe
knockout phenotypes start to emerge (Hagelkruys et al., 2014).
Wemapped the human ASD candidates onto their unambiguous
one-to-one mouse orthologs (341 of 378 ASD candidate genes
mapped) and observed that these ASD candidate orthologs dis-
played significant downregulation in the mouse brain at E14.5
when both Hdac1 and Hdac2were knocked out (p = 2.4e-7, Wil-
coxon rank-sum test, relative to mouse genes with one-to-one
human orthologs; Figure 3A).
Since HDAC2 is implicated in ALZ (Gra¨ff et al., 2012), we
further examined whether the above downregulation was
specific for ASD. We analyzed genes implicated in intellectual
disability (ID, 401 genes), SZ (499 genes), and ALZ (613 genes)
(Supplemental Experimental Procedures). The downregulation
was absent for the genes implicated in ID, ALZ (Figure 3A),
but was milder in SZ (Figure 3A). Notably, mouse orthologs
of the ALZ genes displayed significant upregulation in the
Hdac1D/DnHdac2D/Dn double-knockout mutants (p = 1.1e-6,
Wilcoxon rank-sum test), suggesting that Hdac1 and Hdac2
negatively regulate ALZ genes but positively regulate ASD
genes. Specially, as exemplified in Figure 3B, among the down-
regulated genes for ASD, mouse orthologs of many well-estab-
lished ASD genes were significantly involved, including five
(Chd8, Cul3, Dyrk1a, Grin2b, and Tbr1) of the nine high-confi-
dence recurrent hits from a recent exome-sequencing study
with an expanded ASD cohort (Willsey et al., 2013). Genes
involved in language disabilities, Foxp2 and Cntnap2, also ex-
hibited remarkable downregulation. The highly repressed genes
also included Mecp2 (causal for Rett syndrome), Ube3a (causal
for Angelman syndrome), Nlgn3, and the synaptic scaffolding
component Dlg4 (PSD-95, inter-connecting SHANK-neurexin-
neuroligin pathway), whose mouse mutant showed severe
autistic phenotypes (Feyder et al., 2010). In addition, the BAF
complex subunit BAF170 (Smarcc2) also exhibited expression
reduction, regulating cerebral cortical size and thickness
(Tuoc et al., 2013), and this gene harbored de novo CNV and
splicing-site-affecting mutations among individuals with ASD
(Neale et al., 2012; Sanders et al., 2011).
We next examined the transcriptome response inmouse brains
expressing a single allele of either HDAC1 or HDAC2 at E14.5
(mice with Hdac1D/+nHdac2D/D or with Hdac1D/DHdac2D/+n)
(Hagelkruys et al., 2014). Despite the downregulation in.
AB
Figure 3. The Regulatory Role of HDAC1 and HDAC2 in ASD
(A) Log2-fold changes of genes in the embryonic mouse brain (E14.5) upon
Hdac1D/Dn Hdac2D/Dn. Mouse orthologs of human genes implicated in intel-
lectual disability (ID), schizophrenia (SZ), Alzheimer’s disease (ALZ), and
autism spectrum disorder (ASD) were compared with all the mouse genes with
one-to-one protein-coding human orthologs (transcriptome). Statistical sig-
nificance was derived from Wilcoxon rank-sum test.
(B) Representative ASD-implicated genes showing substantial downre-
gulation of the HDAC1 and HDAC2 double knockouts (DKOs; in triplicate)
in mouse embryonic brain compared to the wild-type cells (in duplicate).
Gene expression shown are log2 scale transformed from the original
measurements.Hdac1D/DnHdac2D/Dn mice, the presence of either single allele
restored expression of these ASD candidates to a level similar
to that of the transcriptome background (Figure S2), suggest-
ing that Hdac1 and Hdac2 each individually exert regulation
on the ASD candidate genes. Since mice with a single
Hdac1 allele (Hdac1D/+nHdac2D/D) die at the first day after birth
(P0) accompanied with the dysregulation of genes different
from those at E14.5, we examined the response of the ASD
candidates at P0 upon Hdac1D/+nHdac2D/D and found that
they did not show significant differential expression (Figure
S2). Taken together, we established that HDAC1 and HDAC2
positively regulate ASD gene candidates during early brain
development.CelInteractions Mediated by ASD Candidate Proteins in
Neuronal Cells
To gain more mechanistic insights into ASD, we sought to
identify protein complexes in a neuronal context. Large-scale
profiling of physical protein interactions in specific tissues
or induced pluripotent stem cell (iPSC)-derived neurons is
currently challenging due to the requirement of large number of
cells. We therefore differentiated SH-SY5Y cells into neuron-
like cells (Supplemental Experimental Procedures), which have
been frequently used tomodel neurological and neuropsychiatric
diseases including ASD (Chiocchetti et al., 2014). We confirmed
the neuronal characteristics of thedifferentiated cells by visual in-
spection of neuronal morphology (Figure 4A) as well as by the
overall upregulation of neuron markers upon differentiation (p =
7.7e-5, Wilcoxon rank-sum test) based on our RNA-Seq profiling
(Supplemental Experimental Procedures; Table S3).
For the immunoprecipitation experiments, we targeted 11
ASD-associated genes from the following three broad cate-
gories: group 1, comprising nine genes that have arguably high
confidence in idiopathic ASD (Willsey et al., 2013): ANK2,
CHD8, CUL3, DYRK1A, GRIN2B, KATNAL2, POGZ, SCN2A,
and TBR1, and group 2, encompassing the gene FMR1 (causal
for FXS) encoding for an RNA-binding protein (FMRP) that exerts
translational repression on its target messengers. While more
than 30 proteins have been identified as its interacting partners
(the BioGrid database), most of these interactions were identified
fromY2H assays in vitro or from non-neuronal cells. Hence, iden-
tifying complexes encompassing FMRP in a neuronal context is
expected to elucidate its role in neuropsychiatric diseases.
Group 3 comprises the aforementioned HDAC1 (co-complexed
withHDAC2), whichwas affected by an ASD-associated de novo
CNV (Figure 2A).
These prioritized 11 proteins as baits were subjected to immu-
noprecipitation (IP) in the differentiated SH-SY5Y neuron-like
cells (Table S4), followed by high-resolution MS analysis to iden-
tify their endogenous co-complexed neuronal subunits (Fig-
ure 4A; Supplemental Experimental Procedures). A total of 26
independent proteome-wide co-purification experiments was
performed, including two biological replicates for each of the
11 bait proteins and four independent negative control experi-
ments (Supplemental Experimental Procedures). Among the 11
bait proteins, we successfully recovered seven baits in both bio-
logical replicates in their respective purified immunoisolates
(ANK2, CHD8, CUL3, DYRK1A, FMRP, POGZ, and HDAC1)
and confirmed low abundance of the remaining four unrecovered
bait proteins (GRIN2B, TBR1, SCN2A, and KATNAL2) by both
RNA-Seq and immunoblot assays (Figure S3). Therefore, we
focused only on the seven ASD-associated bait proteins for their
neuronal relevant protein interactions.
After filtering with the peptide identification confidence 90%
and removing themostcommonbackgroundcontaminants (Sup-
plemental Experimental Procedures),we identified2,812putative
PPI pairs from seven bait proteins. These putative interactions
were then scored by SAINTexpress (Mellacheruvu et al., 2013),
which assigned each interacting bait-prey pair with a Bayesian
posterior probability of true interaction by comparing their
MS/MS spectra counts between the seven bait proteins and the
negative controls (Supplemental Experimental Procedures). We
retained 119 interactions (involving 95 prey proteins; Table S5)l Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Inc. 365
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above the probability threshold 80%, which exhibited the stron-
gest enrichment (Figure 4B, p = 3.97e-6, Fisher’s exact test) to-
ward known PPIs (Turinsky et al., 2011). The MS/MS spectral
counts for the 119 high-confidence interactions are shown in Fig-
ure 4C, and the binding specificities with the seven bait proteins
were clearly consistent between the two biological replicates,
with an average fold enrichment of 57.46 relative to the negative
control experiments.
Coordinated Expression of the Identified Interacting
Proteins in the Human Brain
We reasoned that if the identified 119 high-confidence interac-
tions indeed reflect the molecular activities in the human brain,
the interacting proteins are expected to be co-expressed during
brain development as co-expression dictates the quality of the
identified PPIs. We therefore examined the mRNA expression
of the 95 identified prey proteins in Brodmann areas 9, 40 (BA9
and BA40) and the amygdala (AMY) using our published dataset
(Li et al., 2014). We found that the identified prey proteins were
substantially elevated in expression (Figure 4D, p % 9.9e-9,
Wilcoxon rank-sum test), demonstrating their overall activity in
these neuronal brain regions.
Next, we examined two sets of temporal transcriptome data
for brain development: (1) the CORTECON dataset in which
human embryonic stem cells (hESCs) were differentiated into
cortical neurons (van de Leemput et al., 2014) and (2) the Brain-
Span dataset in which expression profiling was performed in the
human neocortex across eight different developmental stages
from the post-conceptual week (PCW) 8–10 (early fetal) to the
postnatal 12 months (Parikshak et al., 2013). For both datasets,
we considered only the protein-coding genes with moderate or
high expression in the brain (mean FPKMsR 1 across develop-
mental stages) and computed pairwise Pearson’s correlation
(R) for each of the 119 high-confidence bait-prey interactions
across the developmental stages. In both CORTECON and
BrainSpan, these interacting proteins showed significantly
increased expression correlation relative to the co-expression
of the seven bait proteins with all the brain expressed pro-
tein-coding genes (p = 1.9e-5 and 0.04 for CORTECON and
BrainSpan, respectively, Wilcoxon rank-sum test; Figure 4E).
Collectively, our analyses demonstrated the overall quality of
the 119 high-confidence bait-prey interactions, which revealed
their co-complex membership in a cellular context.
High-Quality Physical Interactions Form an ASD-
Associated Interactive Network
Although the seven bait proteins were individually identified as
ASD-associated candidates, the 119 bait-prey interactionsFigure 4. Neuronal Proteins Co-complexed with ASD-Associated Prot
(A) The flowchart of the immunoprecipitation experiments followed by mass-spe
(B) The prey proteins co-purified with the baits were examined using a Bayesian
probabilities (R80%) as true interactions are highly enriched for known protein in
from Fisher’s exact test.
(C) The inverse-tangent normalized spectral count of the identified prey proteins
(D) The identified prey proteins exhibited substantially increased expression in neu
(AMY). In each region, a subset of genes with FPKM > 0 was used as background
(E) The identified prey proteins exhibited substantially increased expression correl
transcriptome datasets from Cortecon and BrainSpan were examined; statistica
Celform an interactive network (Figure 5A, except for POGZ).
We observed that 15 prey proteins were shared by at least
two bait proteins, and thus, we tested the null hypothesis
whether the same number of shared proteins would be ex-
pected from non-specific protein interactions. We mimicked
the IP-MS by randomly sampling (to nullify the binding speci-
ficity of interacting proteins) the same number of moderately
or highly expressed brain-expressed genes (FPKM > 1 in
BA9) for each bait protein and observed that these ASD pro-
teins were more likely to target a common set of genes (p <
1e-4, permutation test), suggesting a convergent network un-
derlying the organization of these ASD proteins. One example
is ACOT7, which simultaneously interacted with CHD8, ANK2,
FMRP, and CUL3. These interactions were specific as our anti-
body-based co-IPs confirmed the presence of ACOT7 protein
in the purified cell lysates of the ANK2, FMRP, CUL3, and
CHD8, respectively, but not from the control-IP experiments
(Figure 5B; Supplemental Experimental Procedures). These
validations support the high quality of our interactome data
and suggest that ACOT7 might be implicated in ASD. Further
examination of its expression in the cerebellar vermis, superior
gyrus, and prefrontal cortex (Voineagu et al., 2011) revealed a
substantial expression reduction only in the prefrontal cortex
among the ASD cases relative to the control subjects (p =
0.02, Wilcoxon rank-sum test; Figure 5C), suggesting that the
nonsense mutations observed from CHD8, ANK2, FMR1, and
CUL3 may have a shared molecular etiology with ACOT7 dys-
regulation in ASD. Taken together, the identified network rep-
resents a set of pathways where ASD-associated factors are
likely to converge.
In thewhole network, these interacting prey proteins displayed
a significant enrichment in the proteome of the human postsyn-
aptic density (PSD) (Baye´s et al., 2011) relative to genes with
moderate to high expression (FPKM > 1; Figure 4D) in the BA9,
BA40, AMY regions as well as in the differentiated neuron-like
cells (p < 0.03, Fisher’s exact test; Table S5). The mammalian
phenotypic enrichment test further revealed that mouse mutants
for the 95 prey proteins displayed defects in neuron physiology
(adjusted p = 0.024 by Benjamini-Hochberg’s method), neuron
morphology (adjusted p = 0.05), and embryogenesis (adjusted
p = 3.98e-3) relative to wild-type mice. Overall, these analyses
suggest the significance of the identified interacting proteins in
maintaining neuronal functions.
Increased Mutational Burden of the Identified
Interaction Network
To assess whether the identified prey proteins harbored a
significant number of deleterious mutations in ASD cases,eins
ctrometry analysis.
mixture model. The bait-prey interactions assigned with the highest posterior
teractions curated from the literature. The statistical significance was derived
co-purified with the bait proteins in two biological replicates.
ronal regions, including Brodmann areas 9 (BA9), 40 (BA40), and the amygdala
control. The statistical significance was derived from Wilcoxon rank-sum test.
ation with their respective bait proteins during brain development. The temporal
l significance derived from Wilcoxon rank-sum test.
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we examined the non-synonymous variants from an exome-
sequencing study, which included 505 ASD cases and 491
matched control subjects with unrelated European ancestry
(Liu et al., 2013) (Supplemental Experimental Procedures). We
reasoned that if the mutations converge onto a molecular
network implicated in the disease (rather than individual genes),
two predictions immediately follow: (1) compared with other
genomic regions (genomic background), genes implicated in
the network are more likely to harbor deleterious mutations,
and (2) the increased level of deleterious mutations should
not be observed in unaffected individuals. We tested these pre-
dictions individually.
It is known that subjects with ASD and their matched controls
have almost equal frequencies of common variants (Anney et al.,
2012). We thus examined the variants observed among individ-
uals with ASD, but not in the control subjects. To determine
the statistical significance of the mutational enrichment on the
95 prey proteins, we compiled a list of 9,201 genes whose cod-
ing-sequence (CDS) length and GC content are similar with the
identified prey proteins (p = 0.297 and 0.98 for CDS length and
GC content, respectively, Wilcoxon rank-sum test; Supple-
mental Experimental Procedures). This large set of control genes
allowed us to more accurately estimate a background distribu-
tion of the deleterious non-synonymous mutations in genes pre-
sumably not directly associated with ASD.
We studied 40,830 non-synonymous variants with predicted
mutational effects by MutationTaster (Schwarz et al., 2010),
which were specifically identified in ASD individuals but not
in their matched control subjects. We observed a modest but
statistically significant increase in the fraction of deleterious
(prediction score equal to or greater than 0.99) non-synony-
mous mutations in the network relative to those detected in
the control gene set (Figure 5D; p = 9.3e-3, Fisher’s exact
test; the seven bait proteins were excluded from the analysis).
Conversely, when considering 31,668 variants specifically
observed in the non-ASD control subjects with predicted muta-
tional effects, the fraction of deleterious mutations on this
network was almost identical with the negative control gene
set (Figure 5D; p = 0.79, Fisher’s exact test). Collectively, this
comparative analysis reveals increased mutational burden on
these identified prey proteins and further implicates the interac-
tion network in ASD.
Functional Implication of the Network in Early Fetal
Brain Development
Given the overall co-expression of the interacting proteins in the
neocortex across human brain developmental stages (PCW 8Figure 5. Neuronal Protein Interactome of Seven Key ASD Proteins
(A) High-confidence interaction network is shown for 7 bait proteins (squared node
interactions. Node color indicates biased brain expression in the early fetal (red)
regulated by FMRPI304N causal for FXS. Four interactions mediated by ACOT7 (w
using coimmunoprecipitation.
(B) Coimmunoprecipitation of ACOT7 with CUL3, CHD8, ANK2, and FMRP.
(C) ACOT7 displayed significantly (Wilcoxon rank-sum test) reduced expression in
expression in the superior temporal gyrus and the cerebellar vermis was no long
(D) Increased mutational burden of the deleterious mutations (predicted by Muta
matched control gene sets with similar CDS length and GC content. Comparison
Only the non-synonymous variants specifically observed in each group were con
Celto postnatal 12 months; analyzed in Figure 4E), we examined
whether the network is active in a specific developmental stage.
We used b to denote the ratio of expression in the early fetal
development (PCW 8–10) relative to the mean expression in
the postnatal stages (4, 10, and 12 months), and increased b
indicates more biased expression in the early fetal brain devel-
opment. We observed that the overall network showed a signif-
icant increase in b (red nodes in Figure 5A, and also see the
comparison in Figure 6A; p = 1.4e-12, Wilcoxon rank-sum
test) relative to all the 12,140 genes with moderate or high
expression in the pre-frontal cortex (represented by genes
with FPKM > 1 in BA9). This enrichment was particularly pro-
nounced for proteins interacting with FMRP, HDAC1, and
DYRK1A (p = 6.9e-4, 2.2e-6, and 6.5e-5, respectively, Wilcoxon
rank-sum test; Figure 6A). For HDAC1, members of the NuRD
complex all showed substantial expression bias toward the
early fetal brain development (e.g., HDAC1/2, CHD4, MTA1/2,
and GATAD2A; Figure 5A). Overall, the strongly biased expres-
sion in the early fetal stage suggests an early origin of this
disease.
We further examined the expression dynamics of each bait
protein together with their interacting partners at individual
brain developmental stages (Figure 6B).CUL3 and its interacting
partners exhibited tight expression correlation across brain
developmental stages, reflecting high-dosage sensitivity of
these interacting proteins, and their expression levels were sig-
nificantly repressed in the postnatal 12-month brain. HDAC1,
however, showed a different pattern, in which its expression
was specifically upregulated at PCW 8–10 and was then
repressed across all the other stages (corresponding to its high
b value in Figure 6A). Its interacting proteins showed a similar
pattern, but were more gradually shifted from the highest level
in the early fetal stages to lower expression in the postnatal
stages, corresponding to their elevated expression bias b in Fig-
ure 6A. FMR1 showed the opposite trend; in the prenatal stages,
its expression co-fluctuated with its interacting partners, but
became discordant in the postnatal stages by upregulating the
FMR1 level (Figure 6B).
FMRP Preferentially Regulates Components of the
Network
Since FMRP post-transcriptionally represses protein translation
of its target messengers (Darnell et al., 2011), the observation
of the significant upregulation of FMR1 and the overall down-
regulation of many other proteins in the network at the same
postnatal stages (Figure 6B) led us to hypothesize that FMRP
likely post-transcriptionally regulates genes in this network.s) containing 95 distinct prey proteins (the circled nodes), and 119 co-complex
or postnatal (blue) stages. The white node border indicates genes differentially
hite edge line) with CUL3, CHD8, ANK2, and FMRP were individually validated
the prefrontal cortex in ASD individuals relative to the controls, whereas ACOT7
er significant.
tionTaster) in ASD network. The 95 prey proteins were compared with a set of
s were performed separately in ASD individuals and in the non-ASD subjects.
sidered.
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Figure 6. Analysis of the Identified Neuronal Protein Interaction Network
(A) Analysis of expression bias b (y axis) in early neocortical developmental stage (PCW 8) relative to the postnatal stages (4, 10, and 12months). b values of all the
prey proteins or the interacting proteins with their respective ASD-associated bait proteins indicated were compared with that of brain expressed genes, rep-
resented by genes with FPKM > 1 in BA9; statistical significance derived using Wilcoxon rank-sum test.
(B) Expression dynamics of the proteins interacting with each bait across various brain developmental stages.
(C) Positive correlation between b and FMRP site density for the proteins interacting with HDAC1. FMRP site density is the number of FMRP PAR-CLIP sites in
CDS or UTRs per Kb.
(D) The identified prey proteins are significantly enriched (Fisher’s exact test) for genes harboring FMRP binding sites ablated by FMRPI304N. The comparisons
were made between each gene group and their matched control gene set with similar expression level and cDNA length. Literature curated SFARI genes, ASD-
associated genes in this study, and genes affected by de novoCNVs in ASDprobandswere also analyzed together with the identified prey proteins in the network.
(E) MECP2 repression on the 95 prey proteins in the network. The orthologous prey proteins were significantly (Wilcoxon rank-sum test) upregulated in mouse
cortical neurons upon anti-MECP2 shRNA knockdown, whereas in mock control the orthologous prey proteins displayed insignificance relative to the tran-
scriptome background. The log2-fold change was determined by gene expression after shRNA treatment relative to that after transfection of an anti-luciferases
shRNA control.
(F) A proposed model for the shared molecular basis of the idiopathic and syndromic forms of ASD. The green nodes represent shared interacting pro-
teins with the components of syndromic (red) and idiopathic (blue) ASDs, while gray edges indicate functional dependencies (e.g., physical, regulatory, or
epistatic).This was not only because of the role of FMRP as a repressor,
but also because such a post-transcriptional regulatory mecha-
nism is often employed in eukaryotic cells to reinforce transcrip-
tional logic, serving as a surveillance system to suppress ‘‘leaky’’
transcripts, which otherwise might exhibit dosage fluctuation
that is highly deleterious (Tsang et al., 2007).
We therefore examined FMRP-mediated regulation identi-
fied from the PAR-CLIP system (Ascano et al., 2012).
Compared with FMRP target genes identified by other plat-
forms, only PAR-CLIP was able to identify the exact binding
sites at the nucleotide resolution. Notably, although the PAR-
CLIP experiments were performed on HEK293 cells, many of
these PAR-CLIP results have also been validated using the hu-
man brain tissues, and comparisons also showed that 90% of370 Cell Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Incgenes expressed in these cells were also expressed in human
brain (Ascano et al., 2012). Considering FMRP binding sites
are mostly localized in CDS or the un-translated regions (30
UTRs and 50 UTRs) and that genes with greater length may
have more binding sites, we computed FMRP site density
for each gene in the network, where the number of sites in
CDS and UTRs were normalized by the cDNA length of
each gene. Different from other bait proteins, we observed
that the HDAC1-interacting proteins displayed a significant
positive correlation (R = 0.42, p = 0.02) between the FMRP
site density (number of sites per Kb) and their b values
(expression bias toward the early fetal stage PCW 8–10 rela-
tive to the postnatal stages, Figures 5A and 6A), where genes
highly expressed in the early fetal stage (fold change >2.
relative to the postnatal stages) had the highest density of
FMRP binding sites (Figure 6C). This observation thus sug-
gests a post-transcriptional role of FMRP in controlling the
HDAC1-mediated interactions.
Perturbation of the Interaction Network by the
Syndromic FMRPI304N
Since FMRP is causal for FXS, we asked whether the identified
PPI network could bridge the gap between the idiopathic and
syndromic forms of ASD. The pathogenic mutation FMRPI304N
causing FXS has been analyzed by the PAR-CLIP platform (As-
cano et al., 2012), where the mutant protein exhibited attenu-
ated RNA-binding affinity due to the mutation in its KH2
RNA-binding domain. With the same set of data, a recent study
has developed a hidden Markov model that identified 9,549
transcriptomic locations strongly bound by FMRPWT, but not
by FMRPI304N(Wang et al., 2014). We mapped these sites
onto RefSeq genes and identified 1,925 genes harboring at
least one such site in their CDS or UTRs. Among the 95 prey
proteins identified in our network, 35 were affected by
FMRPI304N (i.e., with substantially reduced binding affinity by
FMRPI304N; Figure 5A), as were 5 (HDAC1, DYRK1A, CUL3,
CHD8, and POGZ) of the seven bait proteins. Our statistical an-
alyses further determined that the number of genes affected by
FMRPI304N was significantly enriched in our network compared
with control genes (matched with similar cDNA length and
expression levels; see Supplemental Experimental Procedures)
(Figure 6D, p = 0.01, Fisher’s exact test), and the enrichment
was specific for our network but was absent in other
ASD-associated genes from multiple sources (Figure 6D; Sup-
plemental Experimental Procedures). Overall, these results
suggest that the interacting proteins (Figure 5A) constitute a
specific molecular network under the post-transcriptional con-
trol of FMRP, and the pathogenic mutation I304N in FMRP
significantly ablates the regulatory mechanism on this network,
contributing to FXS.
Regulation of MECP2 on the Network in Mouse Cortical
Neurons
To further establish the association of the network with syn-
dromic forms of ASD, we tested the regulation of MECP2
onto the interaction network. We re-analyzed the published
data (Lanz et al., 2013), namely the transcriptomic responses
in murine cortical neurons upon individually knocking down
eight ASD-associated genes using shRNAs (short hairpin
RNAs) against Mecp2, Mef2a, Mef2d, Fmr1, Nlgn1, Nlgn3,
Pten, and Shank3. The knockdown efficiency had been re-
ported to achieve at least 75% expression reduction in
quadruplicate experiments. These cortical neurons were ob-
tained from the murine embryonic brain at E16 (corresponding
to human PCW 8, 56–60 days), which makes it possible to
draw parallels to the humans as the network identified in our
study exhibited an overall increased transcriptional dynamics
at PCW 8–10 (the increased b for all the prey proteins;
Figure 6A).
We mapped the 95 prey proteins in the network onto their
one-to-one mouse orthologs and determined their response to
shRNA treatment against each of the eight ASD genes. Fold
changes were computed for gene expression after individualCelshRNA treatment relative to expression after transfection of an
anti-luciferase shRNA control. We observed that mouse ortho-
logs of the prey proteins exhibited significant upregulation
upon Mecp2 knockdown (Figure 6E, FDR = 7.6e-3, Wilcoxon
rank-sum test relative to the transcriptome background, Benja-
mini-Hochberg correction for all the eight shRNA experiments),
whereas the differential expression was absent for all the
other seven ASD-associated genes nor for the mock control
(FDRs R 0.2, Wilcoxon rank-sum test). Close examination
further revealed that the upregulation upon Mecp2 knockdown
was substantial (Figure 6E, median fold change of 2.11), with
Hdac2 and Gatad2a in the NuRD complex changing greater
than 2.5-fold and the neuronal signaling factor Flot2 more
than 3-fold. Overall, these observations suggest considerable
Mecp2 repression on the network in mouse embryonic cortical
neurons.
DISCUSSION
A hallmark of ASD is its extreme locus heterogeneity, where
the recurrence of causal mutations is typically rare within
ASD individuals. Therefore, it is unlikely that it will be possible
to infer the complete genetic architecture of ASD merely based
on individually identified ASD-associated mutations. In a previ-
ous study, we leveraged a human PPI network to derive the
high-level functional modules involving proteins associated
with ASD (Li et al., 2014). In the present study, we provide a
finer grained framework by directly identifying and analyzing
protein complexes that are ubiquitously expressed in human
cells. We then used this information to identify complexes
specifically expressed in human neuronal culture. This analysis
not only allowed us to identify new components and mecha-
nisms involved in ASD, but also uncovered the molecular
convergence underlying the highly heterogeneous mutations
across ASD.
We first analyzed the ubiquitously expressed protein com-
plexes and then identified ASD-associated protein complexes
in neuronal cells, which to our knowledge has not been reported
previously. Importantly, the identified network displayed conver-
gent regulation of FMRP and MECP2 in ASD, suggesting shared
molecular basis between the syndromic and idiopathic forms
of ASD. Although previous studies have observed an overall
enrichment of ASD-associated genes among hundreds to thou-
sands of wild-type FMRP targets (De Rubeis et al., 2014; Iossifov
et al., 2012, 2014; Parikshak et al., 2013), our study provides
several additional insights: (1) we identified FMRP interacting
proteins in neuronal culture (Figure 5A), which are largely distinct
from those identified from in vitro Y2H screens (detailed compar-
ison discussed below); (2) our analysis showed that the neuronal
FMPR-interacting proteins are preferentially expressed in the
early fetal brain (Figure 6A), suggesting an early onset of the
FMRP-mediateddiseases; (3)we showed the effect of syndromic
mutation FMRPI304N on the identified network, suggesting its
etiological contribution to FXS; (4) our study also revealed a
significant correlation between FMRP regulation and fetal
brain expression of the HDAC1-mediated interaction network
(Figure 6B). More importantly, our study shows a heretofore
unreported convergence between the ASD-associated path-
ways and the regulatory network governed by MECP2 causall Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Inc. 371
for Rett syndrome. Taken together, as depicted in Figure 6F, we
propose that genes implicated in the idiopathic and syndromic
forms of ASD have a shared molecular basis through physical
or regulatory interactions with a common set of genes, which
might help explain their overlapping phenotypes on the ASD
spectrum.
In comparison to the Y2H screens (Corominas et al., 2014;
Sakai et al., 2011), our IP-MS approach allowed us to examine
the disease in a more biologically relevant context (i.e., neuronal
cell culture). Consequently, our screen uncovered a number of
interactions not previously identified from Y2H. For example,
the most recent Y2H screen identified five proteins interacting
with FMRP (Corominas et al., 2014), whereas an earlier Y2H
screen identified 22 with FMRP (Sakai et al., 2011), with only
one overlapping (FXR2) between the two Y2H studies. Except
for the well-known FMRP-interacting proteins FXR1 and
FXR2, none of these Y2H screens captured the remaining 30
high-confident prey proteins identified in our IP-MS in the
neuronal culture, highlighting the importance of studying
autism-associated protein interactions in a relevant cellular
context.
Additionally, our investigation specifically pinpointed roles of
two histone deacetylases (HDAC1 and HDAC2) in the NuRD
complex. While their membership in NuRD complex had
been identified in earlier studies (Havugimana et al., 2012;
Xue et al., 1998; Yamada et al., 2014), by targeting HDAC1,
our IP-MS recovered the NuRD complex in differentiated
neuronal culture. We also performed a separate IP-MS screen
for HDAC2 (with six biological replicates) in the neuronal cell
line and confirmed that the overlapping proteins that interact
with both HDAC1 and HDAC2 were mostly the subunits of
the NuRD complex (Table S6). However, for the prey proteins
that specifically interacted with HDAC2 (and not with HDAC1),
none interacted with the network identified in this study (Fig-
ure 5A), nor were they previously associated with ASD. There-
fore, for ASD association, HDAC2 likely has a compensatory
role for HDAC1 in the NuRD complex, which might explain
the compensatory behavior of the two paralogous copies
observed in the embryonic mouse brain (Hagelkruys et al.,
2014).
In conclusion, our integrative analysis revealed molecular
components in ASD and suggests the etiological convergence
of the idiopathic and syndromic forms of ASD. The work pre-
sented here complements the classic mutational analysis in
sequencing studies and highlights the importance of using inte-
grative analyses to reveal themolecular components and biolog-
ical pathways underlying complex diseases. As such, this strat-
egy will be valuable for the analyses of many other complex
diseases.EXPERIMENTAL PROCEDURES
SH-SY5Y cells (ECACC, Sigma-Aldrich) were differentiated into neuron-like
cells by the addition of retinoic acid (RA, Sigma-Aldrich; R2625) and brain-
derived neurotrophic factor (BDNF, eBioscience). ScriptSeq Complete
Gold Kit (Epicenter) was used for RNA-seq library preparation, followed by
sequencingwith Illumina’s HiSeq 2000. The peptidemixtures that co-immuno-
precipitated with the bait proteins were analyzed by a high-resolution Orbitrap
Elite mass spectrometer. All these experiments were performed using two
different cell batches that were separately cultured, grown, and differentiated372 Cell Systems 1, 361–374, November 25, 2015 ª2015 Elsevier Inc(i.e., two biological replicates). Full experimental procedures can be found in
the Supplemental Experimental Procedures.
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